Market Overview

Cantor: Keep Buying Expedia, Investors


In a report published Thursday, Cantor Fitzgerald analyst Naved Khan maintained a Buy rating on Expedia Inc (NASDAQ: EXPE), with a price target of $120, after checks indicated that 2Q was "shaping well."

Checks suggest that hotel room rates across the US as well as Europe have continued their y/y growth in 2Q. "Our tracking of hotel prices in Europe shows that euro-denominated hotel room prices rose ~16% Y/Y in 2Q vs. ~7% in 1Q:15 and ~4% in 4Q:14, reflecting strong demand for European destinations, fueled by local travelers and inflow of foreign tourists," Analyst Naved Khan said.

Khan expects the results to be negatively impacted by the Y/Y decline in euro-USD. In April-May, US hotel occupancy and average daily rate (ADR) continue to move upward, rising around 1.4 percent and 4.8 percent Y/Y, respectively, as compared to 3.1 percent and 4.7 percent in 1Q.

Paid-clicks and mobile visitation for, and Trivago also seem to have recorded good growth during April and May.

There has been robust growth in US mobile visitation for brands Expedia, and Trivago, with total mobile visits in April-May rising 67 percent, 53 percent and 156 percent Y/Y, respectively, Khan quoted comScore as saying.

"While 2Q tends to be back-end weighted, if sustained, we would view these trends positively for 2Q performance," Cantor Fitzgerald noted in its report.

Latest Ratings for EXPE

May 2019DowngradesBuyNeutral
May 2019DowngradesBuyHold
May 2019AssumesHold

View More Analyst Ratings for EXPE
View the Latest Analyst Ratings

Posted-In: Cantor FitzgeraldAnalyst Color Reiteration Analyst Ratings


Related Articles (EXPE)

View Comments and Join the Discussion!

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Disney Sprints To New All-Time High Amid Dividend Increase

Conquering Hemophilia: Novo Nordisk Reports Encouraging Data From Phase III Trial Of NovoEight